Dosage & Administration Efficacy safety testing Drug label Prior authorization Financial assistance

Kadcyla

(trastuzumab)

ado-trastuzumab emtansine 100 MG Injection [KADCYLA]ado-trastuzumab emtansine 160 MG Injection [KADCYLA]

Dosage & administration

* Do not substitute KADCYLA for or with trastuzumab.
* HER2 Testing: Perform using FDA-approved tests by laboratories with demonstrated proficiency.
* For intravenous infusion only. Do not administer as an intravenous push or bolus. Do not use Dextrose (5%) solution.
* The recommended dose of KADCYLA is 3.6 mg/kg given as an intravenous infusion every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity, or a total of 14 cycles for patients with EBC. Do not administer KADCYLA at doses greater than 3.6 mg/kg.
* Management of adverse reactions (infusion-related reactions, hepatotoxicity, left ventricular cardiac dysfunction, thrombocytopenia, pulmonary toxicity or peripheral neuropathy) may require temporary interruption, dose reduction, or treatment discontinuation of KADCYLA.

eficacy, safety & testing

Kadcyla clinical details

Mechanism of Action (MOA)

Clinical Trial: Early Breast Cancer

Efficacy: Early Breast Cancer

Safety Profile: Early Breast Cancer

Preparation and Storage: Early Breast Cancer

Dosing and Administration: Early Breast Cancer

Clinical Trial: Metastatic Breast Cancer

Efficacy: Metastatic Breast Cancer

Safety Profile: Metastatic Breast Cancer

Dosing & Administration: Metastatic Breast Cancer

Preparation & Storage: Metastatic Breast Cancer

drug label

Kadcyla prescribing information

Have more Kadcyla questions?

Submit MSL Request

Learn More

Need to report a Kadcyla issue?

ONLINE FORMReport adverse event

Learn More

prior authorization

Kadcyla Prior authorization resources

Complete Letter of Medical Necessity

NOT PROVIDED BY BRANDCoverage Authorization Request

Coverage Authorization Appeals

Learn More

Benefits investigation

Prescriber Service & Patient Consent Form

Prescriber Service Form - Online Portal

Patient Consent Form - English

Patient Consent Form - Spanish

Learn More

Reimbursement help (FRM)

NOT PROVIDED BY BRANDReimbursement help (FRM) resources

Learn More

financial assistance

Kadcyla Financial assistance options

Co-pay savings program

commercial only

Prescriber Service & Patient Consent Form

Prescriber Service Form - Online Portal

Patient Consent Form - English

Patient Consent Form - Spanish

Enroll in Patient Savings Program

Learn More

Overview

Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)

Patient benefit

A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max

Patient eligibility

Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance

How to sign up

Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form

Bridge program

commercial only

Learn More

Overview

Provide patient immediate access to therapy during an insurance delay (typically new starts; some may cover change in insurance)
Limited time/ fill (typically 7-30 days; some may offer additional fill for continued delay up to certain limit)

Patient benefit

100% free (outside of insurance)

Patient eligibility

HCP must enroll patient
May be limited to commercially insured patients (i.e., no government beneficiaries); some programs may allow government beneficiaries

How to sign up

Typically HCP assisted enrollment (via form)

Foundation programs

under insured

no insurance

goverment insurance

65+

Prescriber Service & Patient Consent Form

Prescriber Service Form - Online Portal

Patient Consent Form - English

Patient Consent Form - Spanish

Genentech Prescriber Foundation Form

Independent Financial Support Programs

Learn More

Overview

Charitable 501(c)(3) organizations provide direct cost-sharing and other support (e.g., travel, counseling) through disease-state funds to indigent patients on first-come first-served basis
These organizations may receive financial contributions from drug manaufacturers for particular disease-state funds that cannot provide funds directly to patients - the foundation must be independent/unaligned

Patient benefit

Patients apply for grants that cover a portion (or all) of their out-of-pocket costs (deductibles and co-pays) until the grant is exhausted

Patient eligibility

Patients must apply and meet eligibility criteria including income level (typically a multiple of federal poverty line), specific diagnosis, insurance status, etc.

How to sign up

Patients submit proof of out-of-pocket drug costs to charities for reimbursement

patient education

Kadcyla Patient education

Getting started on Kadcyla

NOT PROVIDED BY BRANDInstructions For Use: HER2+ Early Breast Cancer

NOT PROVIDED BY BRANDInstructions For Use: HER2+ Metastatic Breast Cancer